Company Monitoring Page for Eisai

latest headlines for company on cafepharma

With bigger fish to fry, Eisai unloads US rights to epilepsy drug Fycompa to Catalyst
Fierce Pharma
Tue, 12/20/22 - 11:14 am
Tags:
Eisai, Fycompa, Catalyst Pharmaceuticals, epilepsy
CTAD 2022 – lecanemab data hold up, with a big but
EP Vantage
Thu, 12/1/22 - 07:01 pm
Tags:
Biogen, Eisai, Alzheimer's disease, CTAD, lecanemab, clinical trials
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
BioPharma Dive
Tue, 11/29/22 - 10:58 pm
Tags:
Biogen, Eisai, Alzheimer's disease, lecanemab
Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal
Fierce Biotech
Mon, 11/28/22 - 07:51 pm
Tags:
Biogen, Eisai, clinical trials, patient death, lecanemab, Alzheimer's disease
Lilly powers through final stretch in critical Alzheimer's race
Fierce Biotech
Tue, 11/1/22 - 07:02 pm
Tags:
Eli Lilly, Alzheimer's disease, donanemab, lecanemab, Eisai
Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report
Fierce Biotech
Mon, 10/31/22 - 10:30 am
Tags:
Eisai, patient death, lecanemab, Alzheimer's disease, clinical trials
Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success
Bloomberg
Wed, 10/19/22 - 10:35 am
Tags:
Roche, Pharma CEOs, Severin Schwan, Alzheimer's disease, Eisai, gantenerumab, lecanemab
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
Tags:
FDA, Biogen, Eisai, Alzheimer's disease, Gilead Sciences, HIV, Mirati Therapeutics, lung cancer, lecanemab, lenacapavir, adagrasib
Eisai cuts the ribbon on $69M injectable drug delivery facility
Fierce Pharma
Tue, 10/11/22 - 10:26 am
Tags:
Eisai, injectables, drug delivery, R&D
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
Tags:
biopharma stocks, AbbVie, Alnylam, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Intellia Therapeutics, Regeneron, Roche, Sanofi, Sarepta Therapeutics
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Tags:
Biogen, Eisai, Alzheimer's disease, Arrowhead Pharmaceuticals, Takeda, RNAi, Madrigal, NASH, Ascendis, FDA
Lecanemab can; now the wait for details begins
EP Vantage
Wed, 09/28/22 - 11:45 am
Tags:
Biogen, Eisai, lecanemab, clinical trials, Alzheimer's disease
Biogen/Eisai Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
Stat
Wed, 09/28/22 - 12:04 am
Tags:
Biogen, Eisai, Alzheimer's disease, clinical trials, lecanemab
Eisai inaugurates new US HQ as closely watched FDA Alzheimer's decision draws near
Fierce Pharma
Sun, 08/21/22 - 09:36 pm
Tags:
Eisai, headquarters, Alzheimer's disease, FDA
July Brings Layoffs, Job Creation for the Life Sciences
BioSpace
Wed, 08/3/22 - 09:32 pm
Tags:
layoffs, hirings, Astellas, Pfizer, Eikon Therapeutics, Bayer, Avadel Pharma, Heron Therapeutics, Adverum Biotechnologies, Biogen, Eisai, X4 Pharmaceuticals, Assembly Biosciences
Eisai closing oncology R&D wing H3 Biomedicine for good
Fierce Biotech
Mon, 07/18/22 - 07:23 pm
Tags:
Eisai, oncology, H3 Biomedicine, layoffs, R&D
Biogen-Eisai go for another biomarker approval in Alzheimer's with lecanemab—and snag priority review
Fierce Biotech
Tue, 07/5/22 - 11:58 pm
Tags:
Biogen, Eisai, FDA, biomarkers, Alzheimer's disease, lecanemab
ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC
Pharmaforum
Mon, 06/6/22 - 11:52 pm
Tags:
ASCO 2022, Eisai, antibody-drug conjugate, Bristol Myers Squibb, MORAb-202
Simulation model shows potential clinical value of Eisai drug for patients with early AD
Biopharma Reporter
Mon, 05/9/22 - 10:15 am
Tags:
Eisai, Alzheimer's disease, lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab
Fierce Biotech
Wed, 05/4/22 - 10:33 am
Tags:
Biogen, Aduhelm, lecanemab, Eisai, Alzheimer's disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.